AKRO

Akero Therapeutics Inc

Add to Watchlist

Advanced Chart

54.040

+0.13(0.241%)1D

Line

Candle

YTD

High

54.100

Open

53.950

VWAP

53.99

Vol

1.12M

Mkt Cap

4.33B

Low

53.930

Amount

60.37M

EV/EBITDA(TTM)

Total Shares

69.15M

3.59B

EV/OCF(TTM)

P/S(TTM)

Akero Therapeutics, Inc. is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Efruxifermin (EFX), its lead product candidate for MASH, is being evaluated in three ongoing Phase 3 studies: SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, and SYNCHRONY Real-World in patients with MASH (F1-F4). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.968

-2.19%

-0.990

+10%

-1.013

+17.83%

Estimates Revision

Stock Price

Go Up

+11.93%

In Past 3 Month

10 Analyst Rating

11.44% Upside

Wall Street analysts forecast AKRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AKRO is 60.22 USD with a low forecast of 54.00 USD and a high forecast of 84.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

7 Hold

0 Sell

Moderate Buy

11.44% Upside

Current: 54.040

Low

54.00

Averages

60.22

High

84.00

11.44% Upside

Current: 54.040

Low

54.00

Averages

60.22

High

84.00

H.C. Wainwright

Andrew Fein

initiated

$72

2025-09-04

Reason

H.C. Wainwright

Andrew Fein

Price Target

$72

2025-09-04

initiated

Reason

H.C. Wainwright analyst Andrew Fein assumed coverage of Akero Therapeutics with a Buy rating and $72 price target. Th firm says efruxifermin's cirrhosis reversal and Phase 3 readouts support a bullish share view.

TD Cowen

NULL -> Buy

initiated

$76

2025-08-04

Reason

TD Cowen

Price Target

$76

2025-08-04

initiated

NULL -> Buy

Reason

TD Cowen initiated coverage of Akero Therapeutics with a Buy rating and $76 price target. The firm believes the company's efruxifermin, an FGF21 analog, has a "differentiated" clinical profile and see commercial success in metabolic dysfunction-associated steatohepatitis. Efruxifermin, is in Phase 3 trials with high probabilities of success, the analyst tells investors in a research note.

BofA

Buy

maintain

$63 -> $64

2025-05-27

Reason

BofA

Price Target

$63 -> $64

2025-05-27

maintain

Buy

Reason

Citi

Buy

downgrade

$80 -> $78

2025-05-13

Reason

Citi

Price Target

$80 -> $78

2025-05-13

downgrade

Buy

Reason

Citi lowered the firm's price target on Akero Therapeutics to $78 from $80 and keeps a Buy rating on the shares. The company reported Q1 earnings after it revealed clinical data from its Phase 2b SYMMETRY trial at the European Association for the Study of the Liver conference last week, the analyst tells investors in a research note. The firm says the detailed data showed that efruxifermin treatment led to improvements on multiple noninvasive measures of liver fibrosis, adding on to 96-week topline liver biopsy data released earlier this year.

Morgan Stanley

Overweight

downgrade

$90 -> $84

2025-05-12

Reason

Morgan Stanley

Price Target

$90 -> $84

2025-05-12

downgrade

Overweight

Reason

Morgan Stanley lowered the firm's price target on Akero Therapeutics to $84 from $90 and keeps an Overweight rating on the shares. Q1 results were uneventful, following multiple data updates last week, further confirming robust benefits on fibrosis, while execution across the Phase 3 SYNCHRONY program continues to be on track, the analyst tells investors in a research note. The firm updated its model to reflect the report and recent trends, specifically reducing its initial EFX sales and increasing its outer year sales tot reflect a more conservative view on the timing of a U.S. launch in F5 patients, pending outcomes data.

HC Wainwright & Co.

Ed Arce

Strong Buy

Maintains

$72 → $75

2025-03-03

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$72 → $75

2025-03-03

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Akero Therapeutics Inc (AKRO.O) is -13.84, compared to its 5-year average forward P/E of -9.00. For a more detailed relative valuation and DCF analysis to assess Akero Therapeutics Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-9.00

Current PE

-13.84

Overvalued PE

-5.07

Undervalued PE

-12.94

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.25

Current EV/EBITDA

-9.41

Overvalued EV/EBITDA

-2.50

Undervalued EV/EBITDA

-9.99

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.48

Current PS

54.04

Overvalued PS

5.53

Undervalued PS

-4.57

Financials

Annual

Quarterly

FY2025Q3

YoY :

+10.44%

-90.24M

Operating Profit

FY2025Q3

YoY :

-100.00%

N/A

Net Income after Tax

FY2025Q3

YoY :

-5.71%

-0.99

EPS - Diluted

FY2025Q2

YoY :

-17.46%

-48.25M

Free Cash Flow

Trading Trends

Insider
Hedge Fund
Congress Trading

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

5.4M

USD

3-6

Months

12.0M

USD

6-9

Months

9.3M

USD

0-12

Months

15.6M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

8.8M

USD

Months

0-12

9.6M

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 117.24% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

1.4M

Volume

0-12

Months

5.9M

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

4.1M

Volume

Months

0-12

1.9M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

5.4M

USD

3-6

Months

12.0M

USD

6-9

Months

9.3M

USD

0-12

Months

15.6M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

8.8M

USD

Months

0-12

9.6M

USD

Months

AKRO News & Events

Events Timeline

2025-11-07 (ET)

2025-11-07

07:07:39

Akero Therapeutics Reveals New Results from SYMMETRY and HARMONY Trials

2025-10-09 (ET)

2025-10-09

12:00:41

Akero Therapeutics Sees 16.6% Increase

2025-10-09

10:00:04

Akero Therapeutics Sees 16.5% Increase

News

7.0

11-07Globenewswire

Halper Sadeh LLC Urges Shareholders of JAMF, CADE, AKRO, and GES to Reach Out for Rights Consultation

8.5

11-06Globenewswire

BRODSKY & SMITH INVESTOR ALERT: Announcing Investigations into Qorvo, Inc. (Nasdaq – QRVO), First Foundation Inc. (NYSE – FFWM), Akero Therapeutics, Inc. (Nasdaq - AKRO), and CoreCard Corporation (NYSE - CCRD)